Canton Strategic Holdings (CNTN) Net Cash Flow (2021 - 2026)
Canton Strategic Holdings (CNTN) reported Net Cash Flow of $24.5 million for Q1 2026, up 1086.51% on a YoY basis from $2.1 million in Q1 2025, and down 71.84% quarter-over-quarter from $87.0 million in Q4 2025.
Canton Strategic Holdings (CNTN) Net Cash Flow (2021 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Net Cash Flow for 6 years, with the latest figure at $24.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 1086.51% year-over-year to $24.5 million; the trailing twelve-month figure through Mar 2026 stood at $118.0 million (up 1705.97% YoY), and the FY2025 full-year result was $13.5 million, up 282.71% from the prior year.
- Net Cash Flow for Q1 2026 stood at $24.5 million, down from $87.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $87.0 million in Q4 2025, with the low at -$3.1 million in Q3 2024.
- Historically, Net Cash Flow has averaged $7.0 million across 5 years, with a median of -$1.1 million in 2022.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 24528.08% — and 2025, when it jumped 7272.57%.
- Canton Strategic Holdings' Net Cash Flow stood at -$1.1 million in 2022, then soared by 859.23% to $8.2 million in 2023, then plunged by 114.71% to -$1.2 million in 2024, then jumped by 7272.57% to $87.0 million in 2025, then plunged by 71.84% to $24.5 million in 2026.
- The last three Net Cash Flow figures came in at $24.5 million (Q1 2026), $87.0 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 24.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.50 Mn |
| Mar 31, 2026 | 24.50 Mn |
| Dec 31, 2025 | 86.99 Mn |
| Dec 31, 2025 | 86.99 Mn |
| Sep 30, 2025 | 5.37 Mn |
| Sep 30, 2025 | 5.37 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | -2.48 Mn |
| Mar 31, 2025 | -2.48 Mn |
| Dec 31, 2024 | -1.21 Mn |
| Dec 31, 2024 | -1.21 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -531,463.00 |
| Jun 30, 2024 | -531,463.00 |
| Mar 31, 2024 | -2.51 Mn |
| Mar 31, 2024 | -2.51 Mn |
| Dec 31, 2023 | 8.25 Mn |
| Dec 31, 2023 | 8.25 Mn |